Clinical data
Investigational
Identifiers
4-amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
C8H10FN3O3S
247.24 g·mol−1
3D model (JSmol)
c1c(c(nc(=O)n1[C@H]2CS[C@H](O2)CO)N)F
InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m1/s1
Key:XQSPYNMVSIKCOC-RITPCOANSA-N
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1] It is the enantiomerofemtricitabine, a widely used NRTI, meaning that the two compounds are mirror images of each other.
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))
2nd generation
2nd generation
Pharmacokinetic boosters
Experimental agents
Other
Failed agents